• Wed, May 11, 2022
Brian Abrahams Maintained (XENE) at Buy with Decreased Target to $41 on, May 11th, 2022
Brian Abrahams of RBC Capital, Maintained "Xenon Pharmaceuticals Inc." (XENE) at Buy with Decreased Target from $43 to $41 on, May 11th, 2022.
Brian, nor any peers, have made any analyst calls on XENE in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30